In short
A new clinical trial is underway to assess the effectiveness and safety of BAY 3283142, a potential treatment for chronic kidney disease. This study aims to determine how well the drug reduces albumin levels in urine, a key indicator of kidney function. The trial will involve patients with chronic kidney disease and will compare different doses of BAY 3283142 to a placebo, in addition to standard care treatments.
At a glance
- Drug Name
- BAY 3283142
- Condition Studied
- Chronic Kidney Disease
- Main Goal
- Reduce urine albumin levels
- Study Design
- Phase 2b, randomized, placebo-controlled, double-blind
- Duration
- 16 weeks
- Primary Outcome
- Change in urine albumin-creatinine ratio (UACR)
- Secondary Outcomes
- Changes in kidney function (eGFR), safety assessment
What is BAY 3283142?
BAY 3283142 is a new drug being developed by Bayer AG to treat chronic kidney disease (CKD). It is currently undergoing clinical trials to evaluate its effectiveness and safety. The drug is being tested in the form of coated tablets that are taken orally (by mouth).
Target Condition: Chronic Kidney Disease
Chronic kidney disease is a long-term condition where the kidneys don't work as well as they should. This can lead to various health problems, including the presence of a protein called albumin in the urine. The main goal of BAY 3283142 is to reduce the amount of albumin in the urine of people with CKD.
How BAY 3283142 Works
While the exact mechanism of action is not specified in the trial information, BAY 3283142 is being tested for its ability to reduce albuminuria. Albuminuria is the presence of too much albumin in the urine, which is a sign of kidney damage. By reducing albuminuria, the drug aims to improve kidney function in patients with chronic kidney disease.
Clinical Trial Details
The clinical trial for BAY 3283142 is a Phase 2b study, which means it's testing different doses of the drug to find the most effective and safe dose. Here are some key details about the trial:
- It's a double-blind study, which means neither the patients nor the doctors know who is receiving the actual drug or a placebo (a dummy pill with no active ingredient).
- The study will last for 16 weeks (about 4 months).
- Patients will be randomly assigned to different groups, including a placebo group and groups receiving different doses of BAY 3283142.
- Some groups may have their dose increased during the study.
Eligibility Criteria
To participate in this study, patients must meet certain criteria. Here are some of the main requirements:
- Be 18 years of age or older
- Have moderately reduced kidney function (measured by a test called eGFR)
- Have a certain amount of albumin in their urine (measured by a test called UACR)
- Be taking specific medications for their condition, such as ACE inhibitors or ARBs
There are also conditions that would prevent someone from participating, such as very low or very high blood pressure, certain liver problems, or specific kidney diseases that require different treatments.
Potential Benefits
The main potential benefits being studied for BAY 3283142 include:
- Reduction in the amount of albumin in the urine, which could indicate improved kidney function
- Potential slowing of the decline in kidney function over time
These benefits are being measured through various tests during the study, including regular checks of urine albumin levels and kidney function.
Safety Considerations
As with any new drug, safety is a crucial aspect of the study. The researchers will be closely monitoring:
- Any side effects that occur during the treatment
- Serious adverse events
- Any side effects that lead to patients stopping the treatment
It's important to note that as this is a Phase 2b trial, the full safety profile of BAY 3283142 is not yet known. The study aims to gather more information about both the effectiveness and safety of this new drug.